Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials.
Now, new findings show that a combination therapy of two miRNAs, let-7 and miR-34, suppressed tumor growth in an animal model of non-small-cell lung cancer, offering a promising therapeutic avenue for this extremely aggressive malignancy.
Currently reported online in the journalOncogene, the study provides two important examples of basic science discoveries making their way to the clinical setting and offers the possibility of a less toxic and more direct method to target multiple biologically relevant pathways to which tumor cells have become addicted.
